secwatch.observer — SEC 8-K summary
======================================

Issuer:     DICE Therapeutics, Inc. (—)
CIK:        0001645569
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001193125-23-206894
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eli Lilly completes acquisition of DICE Therapeutics for $48.00 per share; DICE now wholly owned subsidiary
--------------------------------------------------------------------------------

- Tender offer closed with 42,265,390 shares validly tendered (~88.4% of outstanding).
- All outstanding shares converted into right to receive $48.00 per share in cash.
- DICE's common stock to be delisted from Nasdaq and deregistered under Exchange Act.
- Board of directors replaced by Philip L. Johnson, Gordon J. Brooks, Michael C. Thompson.
- Equity incentive plans, stock purchase plan, and ATM offering agreement terminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645569/000119312523206894/0001193125-23-206894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645569/000119312523206894/d502246d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-206894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer